Dear APSARD Colleagues:

It is my pleasure to welcome you to the 2020 Meeting of the American Professional Society of ADHD and Related Disorders! APSARD is the premier, multidisciplinary organization devoted to the advancement of both the science and clinical practices benefitting individuals with ADHD and comorbid disorders across the lifecycle. This year's program is enriched with state-of-the-art plenaries and symposia addressing key issues affecting the field. As always, we will also have a wide range of posters covering emerging research in ADHD that will offer the opportunity to interact with the presenters and networking opportunities with prominent investigators, clinicians, and colleagues from around the globe who all come to APSARD.

Despite increasing awareness of ADHD in all age groups, huge educational gaps remain among primary and specialty care providers, and there is limited access to evidence-based knowledge, especially in adults and older adults. Controversy, biases and misinformation continue to handicap our field. We need your help in broadening the reach of APSARD and achieving our scientific and educational goals.

Please introduce yourself to any board member or officer if you have suggestions or feedback and ask about volunteering for APSARD committees. We also hope you will participate in our educational activities throughout the year, refer colleagues for membership, and become more involved through the year.

I know you will enjoy the meeting and interacting with your APSARD colleagues.

With warm regards,

Joseph Biederman, M.D.
APSARD President
Welcome to the APSARD Annual Meeting

On behalf of the APSARD Annual Meeting Program Committee, we are delighted to welcome you to the 2020 APSARD Annual Meeting.

The annual APSARD meeting is a major crossroads for experienced clinicians and prominent researchers in the area of ADHD and its related disorder. We focus on presenting the latest research findings which can impact clinical practice now as well as innovative work that will shape the future of the field. This year meeting will cover many keys areas impacting people with ADHD: development of new drugs, sleep, cannabis use and its impact on ADHD, managing difficult patients, and discussions of controversies in our field. Below is a summary of important topics we will cover.

- **Friday, January 17**
  - Opening Plenary: *Perinatal and Early Life Issues in ADHD*
  - Welcome Reception

- **Saturday, January 18**
  - International Breakfast
  - President’s Summary
  - Plenary Session: *New FDA Guidance and Initiatives – Overview and Discussion*
  - Lifetime Achievement Award Plenary: Eric Taylor, MA MB FRCP FRCPsych(Hon) FMedSci
  - Poster Presentations with Lunch – Including a Data Blitz Session
  - Symposium Sessions:
    - ADHD and Autism: New Insights on Their Relationship
    - *Are Differences in Long-acting Stimulant Formulations Clinically Meaningful?*
  - Meet the Experts Sessions: Psychosocial and Pharmacotherapy
  - Reception

- **Sunday, January 19**
  - APSARD Business Meeting
  - Plenary Sessions:
    - Clinical and Pharmaco-epidemiologic Studies of ADHD Medication Treatment: Comparative Efficacy/Tolerability, Functional Consequences, Usage Patterns and Real-World Outcomes
    - Understanding Barriers of Care in ADHD the Report of the Office of the Inspector General
  - Lunch Discussion Groups
    - Too Much or Not Enough? Managing Complex Pharmacology in Difficult Cases
    - Role of Neuropsychology in Assessment of ADHD: Clinical Discussion
  - Symposia Sessions:
    - Sleep Challenges in ADHD
    - ADHD and Cannabis/CBD

Organization

- The meeting is sponsored by the American Society for ADHD and Related Disorders (APSARD).
  - The Program Committee develops program content and invites speakers, evaluates submitted proposals.
- Parthenon Management Group organizes the APSARD Annual Meeting.

The APSARD Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Most importantly, please join us and become a member if you are not already!

Best Regards,

Steven Pliszka, M.D.
UT Health Science Center at San Antonio
Get Connected

Download the mobile app for the 2020 APSARD Annual Meeting

Search “APSARD2020” in the App Store for iPhones
And Google Play Store for Androids today!

The mobile app is a tool that will allow you to browse the Annual Meeting Schedule, view abstracts, and plan your agenda for the meeting.

- Tap the Program icon to search the schedule by date and time. Tapping a session will show additional information such as speakers and abstracts.
- Use the Attendees icon to view the APSARD attendee list.
- Tap the Info icon to view helpful documents such as a Dining Guide, maps of the meeting space and the neighborhood around the hotel, and a list of presenter disclosures.
- The Facebook and Twitter icons will connect you directly to APSARD social media.
- Logging into the app will allow you to “pin” sessions to your schedule that can be uploaded to your phone calendar.

APSARD 2020 Wi-Fi
Network: Marriott CONFERENCE
Password: apsard2020
TABLE OF CONTENTS

Meeting Space Maps ...................................................... XX
Award Winners and Featured Speakers .......................... XX
Acknowledgements .......................................................... XX
Meeting Announcements ............................................ XX
Friday, January 17, 2020 .................................................. XX
Saturday, January 18, 2020 ............................................. XX
Sunday, January 19, 2020 ................................................ XX
Posters ................................................................. XX
Author Index .......................................................... XX
Notes ................................................................. XX

Disclosures for all APSARD presenters can be viewed at www.APSARD.org

Page 3
MEETING SPACE MAPS

MEZZANINE LEVEL

EXHIBITION LEVEL
Award Winners and Featured Speakers

Lifetime Achievement Award

Martha Bridge Denckla, M.D.

Kennedy Krieger Institute / Neurology at Johns Hopkins University School of Medicine

Dr. Denckla graduated *summa cum laude* from Bryn Mawr College and went on to graduate *cum laude* from Harvard Medical School in 1962, after which she trained with Dr. Norman Geschwind in behavioral neurology. Dr. Denckla served residencies at Beth Israel Hospital and Veterans Administration Hospital, both in Boston, as well as Georgetown University Medical Center in Washington DC. After positions in neurology at the College of Physicians and Surgeons in New York, she was on the faculty of Harvard Medical School and served as the director of the Learning Disabilities Clinic at Boston Children’s Hospital. After moving to Maryland in 1979, Dr. Denckla took a position at NINDS/NIH to serve as Chief of the Section on Autism and Related Disorders. She came to the Kennedy Krieger Institute and Johns Hopkins University in 1987 and has since served as Director of the Developmental Cognitive Neurology Department at the Kennedy Krieger.

Since 2008, Dr. Denckla has devoted the time and effort previously spent in the role of Research Principal Investigator to the transfer of information on the developing brain and its milder learning differences to educators, including five years as Adjunct Professor in the Johns Hopkins University School of Education. In this role, she taught fellows in the Kennedy Krieger Institute Center for Innovation and Leadership in Special Education, and consulted to the Fairfax County, Virginia Public Schools on dyslexia.

Dr. Denckla is a past president of both the International Neuropsychology Society and the Behavioral Neurology Society. Dr. Denckla has been awarded the Lucy G. Moses Prize in Clinical Neurology at Columbia University, the Norman Geschwind Memorial Lectureship at Orton Society, the Rita G. Rudel Memorial Lectureship at Columbia University, the Herbert Birch Memorial Lectureship at the International Neuropsychology Society, the Soriano Guest Lectureship of the American Neurological Association and the Bernard Sachs Lectureship of Child Neurological Society. She was the American Academy of Mental Retardation Research Center awardee and in 2013 won the career award given on the occasion of the 50th anniversary of the Learning Disabilities Association (LDA). In 2015, Dr. Denckla was recognized by Johns Hopkins University as its first woman Professor of Neurology and fifteenth woman to be full Professor there in the history of the Medical School.
AWARD WINNERS

Recipient of the Best Paper in the
Journal of Attention Disorders Award

Adult Outcome of ADHD: An Overview of Results From the MGH Longitudinal Family Studies of Pediatrically and Psychiatrically Referred Youth With and Without ADHD of Both Sexes

Mai Uchida, Thomas J. Spencer, Stephen V. Faraone, and Joseph Biederman

Mai Uchida, M.D.
Massachusetts General Hospital

Dr. Mai Uchida is Assistant Professor of Psychiatry at Harvard Medical School and, Staff Psychiatrist in the Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD. Dr. Uchida is a dedicated clinician to both children and adults. She also conducts research to better understand and advance care for various psychiatric disorders.

Her research career focus has been on the characteristics, longitudinal course and treatment of unipolar and bipolar pediatric depression. In collaboration with Drs. John and Susan Gabrieli at MIT, she has published on the fMRI-based biomarkers of the risk for development of major depression and received the First Prize Department of Psychiatry Award of MGH as well as the DuPont Warren Fellowship and Livingston Award for her works on this topic. She has done clinical and neuroimaging-based investigation of emotional dysregulation and has received the Louis V Gertsner Award for this work. She has multiple publications on evaluations of screening tools, longitudinal follow ups and systematic reviews on pediatric depression.

Another area of Dr. Uchida’s expertise is in adult and pediatric Attention-Deficit/Hyperactivity Disorder (ADHD). She is also the recipient of the Elaine Schlosser Lewis Award from the American Academy of Child and Adolescent Psychiatry to investigate the utilization of health technology in improving management of ADHD.

In addition, Dr. Uchida is a committed advocate for mental health. She has articulated her thoughts in a number of international publications, including the International Herald Tribune and Asahi Shimbun, on topics ranging from suicide prevention and informed consent to the experience of being a Japanese female physician in America.
AWARD WINNERS

Travel Awardees

Anne Arnett, Ph.D.
University of Washington

Laura Eddy, Ph.D.
University of North Carolina Greensboro

Weam Fageera, M.Sc.
McGill University

Jonathan Hess, Ph.D.
SUNY Upstate Medical University

Agnieszka Mlodnicka, Ph.D.
University of California Davis

Michael Tate, M.A.
City College of New York

Lea Taylor, B.A.
Syracuse University

Kelsey Wiggs, B.A., B.S.
Indiana University

Developmental-Behavioral Pediatrics APSARD Award

Nicholas Fogleman, M.S.
Cincinnati Children’s Hospital Medical Center
FEATURED SPEAKERS

Friday, January 17, 2020 from 5:30 p.m. – 7:30 p.m.
Why Are We (Not) Waiting? New Perspectives on the Neuroscience of Impulsive Choice in ADHD
Thurgood Marshall Ballroom

King’s College London

Edmund Sonuga-Barke is currently Professor of Developmental Psychology, Psychiatry and Neuroscience working in the Department of Child and Adolescent Psychiatry at the Institute of Psychology, Psychiatry and Neuroscience, King’s College London. He also holds Visiting Chairs at Ghent University, Aarhus University and the University of Sussex. He is Editor in Chief of the Journal of Child Psychology and Psychiatry.

His work integrates Developmental Psychopathology and Neuroscience perspectives to employing basic developmental science approaches to study the pathogenesis of neuro-developmental and mental health conditions; their underlying genetic and environmental risks, mediating brain mechanisms and developmental outcomes. He has a particular interest in ADHD and related disorders.

In 2016, Prof Sonuga-Barke was elected a Fellow of the Academy of Medical Sciences.
FEATURED SPEAKERS

Friday, January 17, 2020 from 5:30 p.m. – 7:30 p.m.
Pills, Skills and Behaviours: Exploring the Psychopharmacology of Impulsivity
Thurgood Marshall Ballroom

David Coghill, M.D.
University of Melbourne

Dave Coghill took up post as Chair of Developmental Mental Health at the University of Melbourne in February 2016. Before this he was professor of child and adolescent psychiatry at the University of Dundee. He is a child and adolescent psychiatrist by training. His research focuses on developing a better understanding of the pathophysiology of ADHD, conduct disorder and depression using a range of approaches including neuropsychopharmacology, neuroimaging and genetics and developing and personalizing approaches to the treatment of child and adolescent mental health problems through the development of biomarkers, neurocognitive phenotypes, clinical trials, pharmacoepidemiology and patient reported outcomes. He has maintained a strong clinical presence and has worked hard to develop clinical pathways that facilitate the rapid transfer of research evidence into routine clinical practice. In addition to his academic role at the University of Melbourne where he is Deputy Head of the Department of Pediatrics, he is part of the neurodevelopmental disorders team at The Royal Children’s Hospital, Melbourne.
FEATURED SPEAKERS

Saturday, January 18, 2020 from 9:00 a.m. – 11:00 a.m.
*Catecholamine Regulation of Prefrontal Cortex: Relevance to Etiology and Treatment of ADHD*
Thurgood Marshall Ballroom

Amy Arnsten, Ph.D.
Yale Medical School

Dr. Arnsten is an expert on the molecular regulation of the prefrontal cortical circuits most impacted by ADHD. Arnsten received her undergraduate degree in Neuroscience from Brown University in 1976, and her Ph.D. in Neuroscience from UCSD in 1981. She did a brief post-doctoral fellowship with Susan Iversen at Cambridge University, UK before becoming a post-doctoral fellow with Patricia Goldman-Rakic at Yale, studying neuromodulatory influences on the primate prefrontal association cortex. Arnsten is currently Professor of Neuroscience at Yale Medical School, with joint appointments in Psychiatry, Psychology and the Yale Child Study Center. Arnsten is the recipient of the Goldman-Rakic Prize for Outstanding Research in Cognitive Neuroscience, and a member of the National Academy of Medicine. Arnsten is one of the few basic researchers whose work in animals has successfully translated to human therapies: guanfacine (Intuniv™) for the treatment of ADHD and related prefrontal cognitive disorders, and prazosin for the treatment of PTSD.
**FEATURED SPEAKERS**

Saturday, January 18, 2020 from 9:00 a.m. – 11:00 a.m.
*The Relevance of Biological and Environmental Risk Factors in the ADHD*
Thurgood Marshall Ballroom

**Joel Nigg, Ph.D.**
Oregon Health & Science University

Joel Nigg, Ph.D., is a Professor of Psychiatry and Behavioral Neuroscience and Director of the Division of Psychology at Oregon Health & Science University in Portland, Oregon. He obtained an AB degree from Harvard, MSW from The University of Michigan, and Ph.D. from UC Berkeley. He is a Fellow in the Society for Psychological Science, has served on numerous journal editorial boards, and his work has been continuously funded by NIMH for over 20 years. His team has published some 200 papers related to ADHD; the work is most known for contributions related to neuropsychology, cognition, and temperament as well as work on heterogeneity, in relation to ADHD.
FEATURED SPEAKERS

Saturday, January 18, 2020 from 9:00 a.m. – 11:00 a.m.
Comorbidity of Attention Deficit Disorder and Physical Conditions: Explanations and Impact
Thurgood Marshall Ballroom

Kathleen Merikangas, Ph.D.
National Institutes of Health

Dr. Merikangas is Senior Investigator and Chief of the Genetic Epidemiology Branch in the Intramural Research Program at the National Institute of Mental Health (NIMH) with expertise in epidemiology, genetics and clinical psychiatry. Her research involves large scale community studies of patterns of sleep, physical activity, and both mental and physical conditions in adults and youth; multigenerational family studies designed to identify the core features and biomarkers of bipolar spectrum disorders. Their work on the application of mobile technologies to examine patterns of motor activity, mood and sleep in mood disorders has led to their coordination of a collaborative network examining motor activity and health, the Motor Activity Research Consortium on Health (mMARCH) in adults and youth. With several other labs in the Intramural Program at NIMH, she is leading a cross-species program of research on genetic and environmental influences on motor activity and related homeostatic systems.
FEATURED SPEAKERS

Sunday, January 19, 2020 from 9:00 a.m. – 10:30 a.m.
Genetics of ADHD and Implications for Educating Patients and Managing the Disorder
Thurgood Marshall Ballroom

Stephen Faraone, Ph.D.
SUNY Upstate Medical University

Stephen Faraone, Ph.D., is a Distinguished Professor in the Departments of Psychiatry and Neuroscience & Physiology at SUNY Upstate Medical University. He is also Senior Scientific Advisor to the Research Program Pediatric Psychopharmacology at the Massachusetts General Hospital and a lecturer at Harvard Medical School. Prof. Faraone founded the ADHD Subgroup of the Psychiatric Genomics Consortium (PGC) and was a founding member of the PGC Coordinating Committee. He is also Editor of Neuropsychiatric Genetics. Prof. Faraone studies the nature and causes of mental disorders in childhood and has made contributions to research in psychiatric genetics, psychopharmacology, diagnostic issues and methodology. An author on over 800 journal articles, editorials, chapters and books, he was the eighth highest producer of High Impact Papers in Psychiatry from 1990 to 1999 as determined by the Institute for Scientific Information (ISI, Science, 2000, Vol 288, pg. 959). In 2005, ISI determined him to be the second highest cited author in the area of Attention Deficit Hyperactivity Disorder (http://www.esi-topics.com/add/interviews/StephenFaraone.html) and in 2013 he was the third most highly cited researcher in psychiatry and psychology (http://academic.research.microsoft.com/). From 2014 to 2018 he has been listed as a highly cited researcher by Thomson Reuters/Clarivate Analytics. His lifetime H-Index as of Feb 2018 was 188.
FEATURED SPEAKERS

Sunday, January 19, 2020 from 9:00 a.m. – 10:30 a.m.
Genetics of ADHD and Implications for Educating Patients and Managing the Disorder
Thurgood Marshall Ballroom

Jim Kennedy, M.D., FRCPC, FRSC
Centre for Addiction and Mental Health, University of Toronto

Dr. Kennedy has training in three major areas: neuroscience, clinical psychiatry, and molecular genetics. His main research interest over the past 25 years has been the identification of susceptibility genes for psychiatric disorders. This has involved extensive hypothesis-based investigations of genetic variation in neurobiological systems known to be involved in psychiatric disorders and addictions. Discoveries from his Neurogenetics laboratory include: 1) the role of the DRD4 gene in ADHD, one of the most consistently replicated findings in all of behavioral genetics; 2) the genetic mapping, and role of the 5HT1B gene in OCD and ADHD; 3) the discovery of the role of the DRD3 gene in predicting Tardive Dyskinesia (issued US patent); 4) prediction of the serious side effect of antidepressant-induced mania (issued US patent); and 5) the role of glutamate system genes (SLC1A1 and GRIN2B) in Obsessive Compulsive Disorder. He has one of the most comprehensive collections of DNAs (N = 34,000) for any one institution in the world in terms of range of psychiatric disorders (N=18) and sub-phenotypes (N=50+). He is leading an ongoing psychiatric pharmacogenetics research program (N=11,200 currently), and research clinical trials (N=600) involving patients with schizophrenia and depression. Thus, he is well-positioned to examine any psychiatric genetic finding to determine its role, if any, across the entire spectrum of mental illnesses and addictions. He has trained over 25 graduate students and 55 research fellows, some of whom are now Full Professors in North America and Japan. Dr. Kennedy is Head of the Molecular Brain Science Department at CAMH that oversees research in genetics, epigenetics, molecular biology, molecular pharmacology, stem cell methods, and molecular bioinformatics. In addition to genetics of most major psychiatric disorders Dr. Kennedy leads the Tanenbaum Centre for pharmacogenetics and the large IMPACT study, including over 500 children and youth, that is developing new genetic tests to predict medication response and side effects.
Dr. Di Martino has a long-standing research interest in autism spectrum disorder and how to best understand its neurobiology using brain imaging and a range of other clinical and cognitive approaches. Her study places a particular emphasis on detecting autism-related differences in brain connectivity that emerge in early childhood, with the goal of identifying objective biological markers that can one day be used to improve early intervention efforts and the selection of treatments.

In order to accelerate the pace of autism research, Dr. Di Martino established and directs the Autism Brain Imaging Data Exchange (ABIDE), which aggregates and shares functional and structural brain imaging data from laboratories around the world. The datasets made available to the scientific community by ABIDE have attracted a broad range of researchers to the study of autism, with expertise ranging from neuroscience and psychology to statistics, mathematics and engineering. New insights are emerging though the studies of ABIDE at a rate of more than a publication per month.

Dr. Di Martino is also a leader in efforts to recognize and understand overlaps in the neural bases of other neurodevelopmental conditions that commonly co-occur with autism, such as attention-deficit hyperactivity disorder. Insights from this work are helping to provide a better understanding of differences in the clinical presentation of autism among individuals, as well as variations in the responses of treatment.

Dr. Di Martino is one of our nation’s most prolific researchers in the neuroimaging of autism, with publications in the most scientifically respected journals in the field of psychiatry, including the JAMA-Psychiatry, American Journal of Psychiatry, Biological Psychiatry and Molecular Psychiatry. She has also received honors and funding support from the National Institute of Mental Health (NIMH) and the Simons Foundation and has been invited to lecture at multiple national and international scientific conferences.
FEATURED SPEAKERS

Sunday, January 19, 2020 from 11:00 a.m. – 12:30 p.m.
Relevance of Imaging in Understanding ADHD
Thurgood Marshall Ballroom

Philip Shaw, Ph.D.
National Human Genome Research Institute

Philip Shaw is an Earl Stadtman Investigator at the Neurobehavioral Clinical Research Section of the National Human Genome Research Institute in Bethesda, United States. His main interest is in the genetic and environmental factors that influence the development of brain and behavior. A focus of his work is one of the most common neuropsychiatric disorders of childhood, attention deficit hyperactivity disorder. He has degrees in experimental psychology and medicine from Oxford University, and a Ph.D. in psychological medicine from the Institute of Psychiatry in London. He completed residencies in internal medicine and psychiatry in England and is a member of both the Royal College of Physicians and the Royal College of Psychiatry.
ACKNOWLEDGEMENTS

Program Committee Members

Steven Pliszka, M.D.
*Program Committee Chair*
University of Texas San Antonio

Joseph Biederman, M.D.
Massachusetts General Hospital

Frances Levin, M.D.
Columbia University Medical Center

Jeffrey Newcorn, M.D.
Icahn School of Medicine at Mount Sinai

Jonathan Poser, M.D.
Columbia University

Karen Seymour, Ph.D.
Johns Hopkins University School of Medicine

Russell Schachar, M.D.
University of Toronto

APSARD Officers and Board

Joseph Biederman, M.D.
*President*
Massachusetts General Hospital

Jeffrey Newcorn, M.D.
*President Elect*
Icahn School of Medicine at Mount Sinai

Mark Stein, Ph.D., ABPP
*Past President*
Seattle Children’s Hospital

Martin Katzman, B.Sc., FRCP(C), M.D.
*Treasurer*
START Clinic for Mood and Anxiety Disorders

Karen Seymour, Ph.D.
*Secretary*
Johns Hopkins University School of Medicine

Lenard Adler, M.D.
NYU School of Medicine

Lawrence Brown, M.D.
Children’s Hospital of Philadelphia

Thomas Brown, Ph.D.
Keck School of Medicine of University of Southern California

Betsy Busch, M.D., FAAP
Tufts University School of Medicine

Ann Childress, M.D.
Center for Psychiatry and Behavioral Medicine, Inc.

Tanya Froehlich, M.D.
Cincinnati Children’s Hospital Medical Center
ACKNOWLEDGEMENTS

APSARD Officers and Board (continued)

David Goodman, M.D.
Johns Hopkins School of Medicine

Andrew Nierenberg, M.D.
Massachusetts General Hospital

John Heiligenstein, M.D.
Pharmaceutical Industry

Anthony Rostain, M.D., MA
University of Pennsylvania

Beth Krone, Ph.D.
Icahn School of Medicine at Mount Sinai

Mary Solanto, Ph.D.
New York University School of Medicine

Greg Mattingly, M.D.
Washington University School of Medicine

Craig Surman, M.D.
Massachusetts General Hospital

Keith McBurnett, Ph.D.
University of California, San Francisco

Roberta Waite, Ed.D
Drexel University

Brooke Molina, Ph.D.
University of Pittsburgh

Margaret Weiss, M.D., Ph.D.
University of British Columbia
Children and Women’s Health Centre
MEETING ANNOUNCEMENTS

Meeting Services

Registration
Thurgood Marshall Foyer on the Mezzanine Level
Friday, January 18  2:00 p.m. – 7:00 p.m.
Saturday, January 19  7:00 a.m. – 6:00 p.m.
Sunday, January 20  7:30 a.m. – 4:00 p.m.

Speaker Ready Room
Taft Meeting Room on the Mezzanine Level
Friday, January 18  2:00 p.m. – 6:00 p.m.
Saturday, January 19  7:00 a.m. – 5:30 p.m.
Sunday, January 20  7:00 a.m. – 3:00 p.m.

The meeting organizers ask that all speakers upload their slides four hours prior to their scheduled presentation time.

Americans with Disabilities Act - It is the policy of APSARD not to discriminate against any person based on disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3083 or send an email to info@apsard.org.

APSARD Mobile App - The APSARD mobile app is now available in the app store for iPhones and in Google Play for Androids. Search APSARD2019 and download today! View the latest schedule, attendee list and abstracts!
Continuing Education Credits

Continuing Education Credits are available for physicians, psychologists, social workers and nurses. Applications for credit must be completed online with the meeting evaluation. The evaluation may be completed after the conference at www.APSARD.org/meeting/program. Evaluations for continuing education credit must be submitted no later than February 15, 2019.

Disclosures are available for all APSARD Annual Meeting presenters online at www.APSARD.org/meeting/program. It is the policy of the APSARD to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Accreditation Statements
This meeting is jointly sponsored by the American Professional Society of ADHD and Related Disorders and AMEDCO.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. NOTE: If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Nurses
In support of improving patient care, this activity has been planned and implemented by Amedco, LLC and the American Professional Society of ADHD & Related Disorders (APSARD). Amedco, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Credit Designation Statement – Amedco, LLC designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credits™ for physicians and 16.25 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Psychologists
This course is co-sponsored by Amedco and APSARD. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program. Maximum of 16.25 hours.

The following state boards accept courses from APA providers for Counselors: AK, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, ID, IL, IN, KS, MD, ME, MO, NC, ND, NH, NE, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WI, WY

AL / Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

MI: No CE requirements

The following state boards accept courses from APA providers for MFTs: AK, AR, AZ, CA, CO, CT, DE, FL, IA, ID, IN, KS, MD, ME, MO, NE, NC, NH, NJ, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WI, WY
MEETING ANNOUNCEMENTS

The following state boards accept courses from APA providers for Addictions Professionals: AK, AR, CO, CT, DC, DE, GA, IA, IN, KS, LA, MD, MO, MT, NC, ND, NE, NJ, NM, NY (outstate held), OK, OR, SC, UT, WA, WI, WY

MA / MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

The following state boards accept courses from APA providers for Social Workers: AK, AR, AZ, CA, CO, DE, FL, GA, ID, IN, KY, ME, MN, MO, NE, NH, NM, OR, PA, VT, WI, WY

Social Workers
Amedco, #1346, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education (ACE) program. Amedco maintains responsibility for the program. ASWB Approval Period: 6/24/2016 to 6/24/2019. Social workers should contact their regulatory board to determine course approval for continuing education credits. Social workers participating in this course may receive up to 16.25 clinical continuing education clock hours.

The following state boards accept courses from ASWB providers for Social Workers: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, NC, ND, NE, NH, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WI, WY

The following state boards accept courses from ASWB providers for Counselors: AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, MA, MD, ME, MO, ND, NE, NM, NH, NV, OK, PA, TN, TX, UT, VA, WI, WY

AL / Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

The following state boards accept courses from ASWB providers for MFTs: AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, MD, ME, MO, NC, NE, NH, NM, NV, OK, PA, RI, TN, TX, UT, VA, WI, WY

MA / MFTs: Participants can self-submit courses not approved by the MAMFT board for review.
The following state boards accept courses from ASWB providers for Addictions Professionals: AK, CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

ADA Statement
ADA accommodations will be made in accordance with the law. If you require ADA accommodations, please indicate what your needs are at the time of registration. We cannot ensure the availability of appropriate accommodations without prior notification.

Grievances
If you would like to file a grievance, complaint or have questions, please contact Chelsea McClain at cmclain@parthenonmgmt.com.

All learners who request continuing education credits by February 15, 2019, should expect to receive their statement of credits via email in March.

The Meeting Evaluation Survey will be available at www.APSARD.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. Your candid input on the 2019 meeting is appreciated as we strive to improve the meeting each year.
MEETING ANNOUNCEMENTS

APSARD would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting.

Pfizer
Shire
Sunovion
Supernus Pharmaceuticals

APSARD Society Support
APSARD would like to thank the following sponsors for their generous donations to the society

Platinum Sponsors

Silver Sponsors

Bronze Sponsors

Exhibitors
Please visit the exhibitors in the Exhibit Hall C Foyer during the meeting.

Akili Interactive
Arbor Pharmaceuticals
CADDRA
CHADD
Ironshore Pharmaceuticals
Qbtech
Rhodes Pharmaceuticals
Shire Pharmaceuticals
Tris Pharmaceuticals
Vaya Pharmaceuticals
SCHEDULE AT A GLANCE

THURSDAY, JANUARY 16, 2020

1:00 p.m. - 6:00 p.m.  Mentor/Mentee Session
                      Harding

FRIDAY, JANUARY 17, 2020

3:00 p.m. - 7:00 p.m.  APSARD Registration
                      Thurgood Marshall Foyer

5:30 p.m. - 7:30 p.m.  Welcome & Opening Plenary: Perinatal and Early Life Issues in ADHD
                      Thurgood Marshall Ballroom

7:30 p.m. - 9:00 p.m.  Reception & Poster Session I
                      Exhibit Hall C
FULL SCHEDULE

THURSDAY, JANUARY 16, 2020

1:00 p.m. - 6:00 p.m.  Mentor/Mentee Session
                      Harding

FRIDAY, JANUARY 17, 2020

1:00 p.m. - 3:00 p.m.  APSARD Board Meeting (Invitation Only)
                       Hoover

2:00 p.m. - 6:00 p.m.  Speaker Ready Room
                       Taft

3:00 p.m. - 7:00 p.m.  Registration
                       Thurgood Marshall Foyer

3:30 p.m. - 5:00 p.m.  APSARD Social Media & Education Committee
                       Meeting (By Invitation)
                       Harding

3:30 p.m. - 5:00 p.m.  APSARD Membership Committee Meeting
                       (By Invitation)
                       Coolidge

3:30 p.m. - 5:00 p.m.  APSARD Psychosocial Subcommittee Meeting
                       (By Invitation)
                       Hoover
PERINATAL AND EARLY LIFE ISSUES IN ADHD
Chair: Joseph Biederman, Massachusetts General Hospital

Early Brain Development and ADHD: Sexual Dimorphism and the Female Protective Effect
Mark Mahone, Kennedy Krieger Institute

Course and Treatment of ADHD During Pregnancy and the Postpartum Period
Lee Cohen, Massachusetts General Hospital

Overall Abstract:
Dr. Mahone’s presentation will highlight recent clinical and research findings related to the developmental neurobiology of ADHD emphasizing sex differences in symptom patterns and functional difficulties. Dr. Cohen’s presentation will review the available data on the course of ADHD during pregnancy and the postpartum period and will provide an algorithm based on available reproductive safety data for using the most widely used pharmacologic therapies for this disorder.

Learning Objectives:
• The audience will learn about developmental neurobiology of ADHD emphasizing sex differences in symptom patterns and functional difficulties.
• The audience will learn about the available data on the course of ADHD during pregnancy and the postpartum period.

7:30 p.m. - 9:00 p.m. Reception & Poster Session I
Exhibit Hall C
***Please see pages xx-xx for a complete listing of posters.
SATURDAY, JANUARY 18, 2020

7:00 a.m. - 8:00 a.m.  International Committee Meeting  
Coolidge

7:00 a.m. - 6:00 p.m.  APSARD Registration Open  
Thurgood Marshall Foyer

8:00 a.m. - 8:45 a.m.  President’s Summary: State of APSARD  
Thurgood Marshall Ballroom

9:00 a.m. - 11:15 a.m.  PLENARY SESSION: NEW FDA GUIDANCE AND INITIATIVES – OVERVIEW AND DISCUSSION  
Thurgood Marshall Ballroom

11:15 a.m. - 11:45 a.m.  Coffee Break  
Exhibit Hall C Foyer

11:45 a.m. - 12:30 p.m.  Lifetime Achievement Plenary with Dr. Eric Taylor  
Thurgood Marshall Ballroom

12:30 p.m. - 1:30 p.m.  Data Blitz Session  
Lincoln 2-4

12:30 p.m. - 2:30 p.m.  Poster Session II with Lunch  
Exhibit Hall C

2:30 p.m. - 4:30 p.m.  Symposium Sessions

ADHD AND AUTISM: NEW INSIGHTS ON THEIR RELATIONSHIP  
Thurgood Marshall Ballroom

ARE DIFFERENCES IN LONG-ACTING STIMULANT FORMULATIONS CLINICALLY MEANINGFUL?  
Lincoln 2-4
SCHEDULE AT A GLANCE

Saturday, January 18, 2020

4:30 p.m. - 5:00 p.m. Coffee Break
Exhibit Hall C Foyer

5:00 p.m. - 6:15 p.m. Meet the Experts Session: Psychopharm
Lincoln 2-4

5:00 p.m. - 6:15 p.m. Meet the Experts: Psychosocial
Thurgood Marshall Ballroom

6:30 p.m. - 7:30 p.m. Reception
Exhibit Hall C
FULL SCHEDULE

SATURDAY, JANUARY 18, 2020

7:00 a.m. - 8:00 a.m.  International Committee Meeting
                      Coolidge

7:00 a.m. - 6:00 p.m.  Registration Open
                      Thurgood Marshall Foyer

8:00 a.m. - 8:45 a.m.  President’s Summary: State of APSARD
                      Thurgood Marshall Ballroom

9:00 a.m. - 11:15 a.m.  PLENARY SESSION: NEW FDA GUIDANCE
                        AND INITIATIVES – OVERVIEW AND
                        DISCUSSION
                      Thurgood Marshall Ballroom

Chair: Stephen Faraone, SUNY Upstate Medical University

New FDA Guidance for ADHD Drug Development: Rationale,
Requirements and Implications for Trial Design
Tiffany Farchione, Food and Drug Administration

Scientific and Regulatory Considerations in Developing Drugs for the
Treatment of ADHD
Thomas Laughren, Massachusetts General Hospital--Clinical Trials
Network and Institute

Prescription Stimulants: What Do We Know about Problematic Use
and is There a Need for Abuse Deterrent formulation?
Marta Sokolowska, Food and Drug Administration/Center for Drug
Evaluation and Research/Office of the Center Director

Panelists:
Lenard Adler, NYU School of Medicine
Matthew Brams, Cingulate Therapeutics
Stephen Faraone, SUNY Upstate Medical University
Sharon Wigal, AVIDA Inc.

Overall Abstract:
The Food and Drug Administration released a draft guidance of research
study principles for methylphenidate and amphetamine drug development
programs. These address pharmacokinetic & pharmacodynamic features of drugs, trial design and inclusion of pregnant women. During this plenary session, Dr. Farchione, the FDA's Acting Director for the Division of Psychiatry Products, will describe the guidance and its rationale. Dr. Laughren, a prior director of the Division will describe some concerns about the new guidance. An expert panel will then discuss the two talks after which the audience will ask questions and provide additional commentary.

Learning Objectives:
- Learn about FDA’s guidance about research study principles for methylphenidate and amphetamine drug development programs.
- Learn about the pros and cons of the FDA’s new guidance on the development of stimulants.

11:15 a.m. - 11:45 a.m. Coffee Break
Exhibit Hall C Foyer

11:45 a.m. - 12:30 p.m. Lifetime Achievement Plenary with Dr. Eric Taylor
Thurgood Marshall Ballroom

Lifetime Achievement Award
Chair: Joseph Biederman, M.D. and Stephen Faraone, M.D.

Abstract: Epidemiology helps clinical professionals to understand the full picture of the problems of ADHD. International differences and long-term perspectives help them to critique current practice. This lecture will be based on some 50 years of clinical and academic involvement with ADHD and other neurodevelopmental disorders. It will present a personal view of how social changes have influenced scientific progress and are creating future challenges. Medication is highly efficacious, but its long-term effectiveness is limited by several obstacles, potentially remediable.

Learning Objective 1: Evaluate current medication practice in the light of international differences.

Learning Objective 2: Learn ways of reacting when individuals are refractory to therapy.
FULL SCHEDULE

12:30 p.m. - 1:30 p.m.  Data Blitz Session
Lincoln 2-4

Chair: Steven Pliszka, UT Health Science Center at San Antonio

12:30 p.m. – 12:35 p.m. Introduction

12:35 p.m. – 12:41 p.m. Does Maternal Depression Actually Distort Perceptions of Child Behavior? An Exploration of the Depression-Distortion Hypothesis
Shana Carrington-Forde

12:41 p.m. – 12:47 p.m. The Association between ADHD Medication and Psychosis
Kelsey Wiggs

12:47 p.m. – 12:53 p.m. Bidirectional Associations between Maternal Mental Health and Child Sleep Problems in Children with ADHD: A Longitudinal Study
Christina Martin

12:53 p.m. – 12:59 p.m. Patterns of Health Services Use before Age 1 in Children Later Diagnosed with ADHD
Matthew Engelhard

12:59 p.m. – 1:05 p.m. Increased Cognitive Enhancing and Reinforcing Effects of Initial Nicotine Exposure Among Young Adults with ADHD Compared to Matched Peers: Laboratory Evidence for a Pathway of Risk for Smoking
Maggie Sweitzer

1:05 p.m. – 1:11 p.m. Increased Behavioral Sensitivity to Repeated Experiences of Punishment in Children with ADHD: Experimental Studies Using the Matching Law
Emi Furukawa

1:11 p.m. – 1:17 p.m. Neurobiological Basis of Reinforcement-Based Decision Making in Adults with ADHD Treated with Lisdexamfetamine Dimesylate
Illiyan Ivanov
FULL SCHEDULE

1:17 p.m. – 1:23 p.m.  Differential Developmental Trajectories of Irritability, Depression and Anxiety in Boys Versus Girls with ADHD
Karen Seymour

12:30 p.m. - 2:30 p.m.  Poster Session II with Lunch
Exhibit Hall C
***See pages xx-xx for a complete listing of posters.

Symposium Sessions

2:30 p.m. - 4:30 p.m.  ADHD AND AUTISM: NEW INSIGHTS ON THEIR RELATIONSHIP
Thurgood Marshall Ballroom

Chair: Steven Pliszka, University of Texas Health Science Center at San Antonio

Longitudinal Studies Mapping both Symptom Domains During Various Parts of the Lifespan
Nanda Rommelse, Radboud University Medical Center

Neural Mechanisms of Executive Function in ADHD and Autism: From Imaging to Treatment
Benjamin Yerys, Children’s Hospital of Philadelphia

Novel Psychopharmacology of ASD with Focus on ADHD
Antonio Hardan, Stanford University

Overall Abstract:
A significant number of children with autism spectrum disorder (ASD) meet criteria for attention deficit hyperactivity disorder (ADHD). In addition, many children with ADHD have multiple symptoms of ASD which interfere with their social functioning. Three presentations will explore the complex nature of the relationship between the disorders. Dr. Rommelse will first present longitudinal studies mapping both symptom domains during various parts of the lifespan. She will propose that co-occurrence need not only to originate from shared etiological factors involved in the onset but also from factors that determine the course of both disorders. The complexities of a lifespan approach towards ASD and ADHD will be discussed. Next,
Dr. Yerys will review the neural mechanisms underlying executive function impairments in ADHD and ASD with magnetic resonance imaging (MRI), with a focus on the role of the frontoparietal and salience brain system as key contributors. This body of work on mechanism also converges with a parallel stream of research to develop innovative treatments designed to target and remediate the executive function system. In the third talk, Dr. Harden will review available treatment targeting core features as well as associated behavioral disorder such attention deficit hyperactivity disorder (ADHD). The role of novel pharmacological interventions will be discussed including oxytocin, arginine vasopressin, N-Acetylcysteine, pregnenolone, and memantine. Data from clinical trials including those targeting inattention and hyperactivity will be reviewed and updated information on recent findings involving old and new compounds will be summarized. Dr. Pliszka will integrate the findings of the symposium and the panel will discuss new directions for research on and treatment of those with comorbid ADHD and ASD.

**Learning Objectives:**
- Summarize findings from cross sectional studies of clinical variables in individuals with ADHD and ASD.
- Understand how longitudinal studies provide a new perspective on the overlap of ADHD and ASD.
- Review the results of neuroimaging studies relevant to the comorbidity of ADHD and ASD.
- Discuss recent advances in the psychopharmacology of ASD, particularly regarding the treatment of inattention and impulsivity in those with ASD.

**2:30 p.m. - 4:30 p.m.**

**ARE DIFFERENCES IN LONG-ACTING STIMULANT FORMULATIONS CLINICALLY MEANINGFUL?**
Lincoln 2-4

**Chair:** Tom Spencer, Massachusetts General Hospital

**Assessing Bioequivalence for Generic Extended Release Formulations**
Andrew Babiskin, Center for Drug Evaluation and Research, Food and Drug Administration
Drug-disease Modeling Approach to Describe the Relationship Between Long-Acting Methylphenidate Exposure and Clinical Response
Roberto Gomeni, PharmacoMetrica

Generic Methylphenidate in Clinical Practice: Perspective on a Shifting Landscape
Ann Childress, Center for Psychiatry and Behavioral Medicine, Inc.

Overall Abstract: TBD

Learning Objectives: TBD

4:30 p.m. - 5:00 p.m. Coffee Break
Exhibit Hall C Foyer

5:00 p.m. - 6:15 p.m. Meet the Experts Session: Psychopharm
Lincoln 2-4

Participants:
Joseph Biederman, Massachusetts General Hospital, Martha Denckla, Kennedy Krieger Institute/Neurology at Johns Hopkins University School of Medicine, Margaret Weiss, Cambridge Health Alliance

5:00 p.m. - 6:15 p.m. Meet the Experts: Psychosocial
Thurgood Marshall Ballroom

Participants:
Russell Barkley, Virginia Commonwealth University Medical Center, Joseph Blader, University of Texas Health Science Center at San Antonio, Scott Kollins, Duke University

6:30 p.m. - 7:30 p.m. Reception
Exhibit Hall C
SCHEDULE AT A GLANCE

SUNDAY, JANUARY 19, 2020

7:00 a.m. – 8:00 a.m.  Advisory Council Meeting
                      Coolidge

7:30 a.m. - 3:00 p.m.  Registration
                      Thurgood Marshall Foyer

8:15 a.m. - 9:00 a.m.  APSARD Business Meeting and Awards Presentation
                      Thurgood Marshall Ballroom

9:00 a.m. – 10:30 a.m.  PLENARY SESSION: CLINICAL AND PHARMACO-EPIDEMIOLOGIC STUDIES OF ADHD MEDICATION TREATMENT: COMPARATIVE EFFICACY/TOLERABILITY, FUNCTIONAL CONSEQUENCES, USAGE PATTERNS AND REAL-WORLD OUTCOMES
                      Thurgood Marshall Ballroom

10:30 a.m. - 11:00 a.m.  Coffee Break
                      Exhibit Hall C Foyer

11:00 a.m. - 12:30 p.m.  PLENARY SESSION: UNDERSTANDING BARRIERS TO CARE IN ADHD THE REPORT OF THE OFFICE OF THE INSPECTOR GENERAL
                      Thurgood Marshall Ballroom

12:30 p.m. - 2:30 p.m.  Lunch & Discussion Groups

  Too Much or Not enough? Managing Complex Pharmacology in Difficult Cases
  Thurgood Marshall Ballroom

  The Role of Neuropsychological Assessment in ADHD: Clinical Discussion
  Lincoln 2-4
12:30 p.m. - 2:30 p.m.  Symposium Sessions

**SLEEP CHALLENGES IN ADHD**
Thurgood Marshall Ballroom

**THE CHANGING LEGAL CLIMATE OF MARIJUANA USE IN ITS IMPACT FOR OUR PATIENTS WITH ADHD**
Lincoln 2-4
FULL SCHEDULE

SUNDAY, JANUARY 19, 2020

7:00 a.m. - 8:00 a.m.  Advisory Council Meeting
Coolidge

7:30 a.m. - 3:00 p.m.  Registration
Thurgood Marshall Foyer

8:15 a.m. - 9:00 a.m.  APSARD Business Meeting and Awards Presentation
Thurgood Marshall Ballroom

9:00 a.m. – 10:30 a.m.  PLENARY SESSION: CLINICAL AND PHARMACO-EPIDEMIOLOGIC STUDIES OF ADHD MEDICATION TREATMENT: COMPARATIVE EFFICACY/TOLERABILITY, FUNCTIONAL CONSEQUENCES, USAGE PATTERNS AND REAL-WORLD OUTCOMES
Thurgood Marshall Ballroom

Chair: Jeffrey Newcorn, Mount Sinai Medical Center

Comparative Efficacy and Tolerability of ADHD Medications in Children/Adolescents and Adults: Systematic Review and Network Meta-Analysis
Samuele Cortese, NYU Langone Health

Chair:

10:30 a.m. - 11:00 a.m.  Coffee Break
Exhibit Hall C Foyer
FULL SCHEDULE

11:00 a.m. - 12:30 p.m. **PLENARY SESSION: UNDERSTANDING BARRIERS TO CARE IN ADHD THE REPORT OF THE OFFICE OF THE INSPECTOR GENERAL**

Thurgood Marshall Ballroom

Chair: Joseph Biederman, Massachusetts General Hospital

*Many Medicaid-Enrolled Children Who Were Treated for ADHD Did Not Receive Recommended Followup Care*

Jamila Murga, HHS OIG

*Should Quality-Of-Care Indicators Have a Demonstrable Relationship to Patient Outcomes?: Service Use and Outcomes from a Large Collaborative Care Project*

Joseph Blader, University of Texas Health Science Center at San Antonio

*Barriers to Care in ADHD: Beyond the DHHS OIG Report*

Peter Jensen, The REACH Institute

Overall Abstract:

In response to congressional request, in August 2019 the DHHS Office of the Inspector General (OIG) issued a report on the healthcare quality for children with ADHD. Using claims data for all Medicaid-insured children across all 50 states and DC for 2014-15, the OIG report examined healthcare quality among close to 900,000 children newly diagnosed with ADHD. The OIG applied the previously-developed “core quality measures” developed by AHRQ (Agency for Healthcare Research on Quality) to examine the extent to which the care of the newly diagnosed children with ADHD conformed to national quality criteria. The OIG’s report highlights the longstanding gap between care for ADHD and its related difficulties that is needed to optimize outcomes vs. what patients actually receive, including the inadequate follow-up care and infrequent behavior therapy. This issue is highly consequential considering that children with ADHD have high rates of academic under attainment, dropping out of school, and needing expensive hospital care. Childhood ADHD is also associated with negative outcomes in adulthood such as increased rates of other mental health problems, criminal behavior, and increased risk for suicide. The annual societal costs of ADHD are estimated at up to $266 billion from loss of productivity, as well as spending in the healthcare, justice, and educational systems. Thus, appropriate treatment and appropriate follow-up of children with ADHD can
help improve these children’s poor outcomes, long-term prognoses, and quality of life. Presentation by Jamila Murga from HHS OIG, Peter Jensen, from the Reach Institute, Joseph Blader from the University of Texas Health Science Center at San Antonio will discuss the relevance and implications of these findings, outline national strategies for improving ADHD healthcare quality, and identify necessary new research efforts to support these activities.

**Learning Objectives:**
- The audience will learn about the findings in the recent OIG report on the healthcare quality for children with ADHD.
- The audience will learn about the significant gaps between recommended care for ADHD and those that are implemented.

**Lunch & Discussion Groups**

12:30 p.m. - 2:30 p.m.  *Too Much or Not enough? Managing Complex Pharmacology in Difficult Cases*
Thurgood Marshall Ballroom

**Chair:** Steven Pliszka, University of Texas Health Science Center at San Antonio

**Speakers:** Craig Surman, Massachusetts General Hospital, Steven Pliszka, University of Texas Health Science Center at San Antonio

12:30 p.m. - 2:30 p.m.  *The Role of Neuropsychological Assessment in ADHD: Clinical Discussion*
Lincoln 2-4

**Chair:** Russell Schachar, The Hospital for Sick Children

**Speakers:** Russell Schachar, The Hospital for Sick Children, Russell Barkley, Virginia Commonwealth University Medical Center, Mark Mahone, Kennedy Krieger Institute, Kevin Antshel, Syracuse University
**Symposium Sessions**

12:30 p.m. - 2:30 p.m.  **SLEEP CHALLENGES IN ADHD**  
Thurgood Marshall Ballroom

**Chair:** Mark Stein, University of Washington

**Sleepy Teens: Recent Advances in Sleep in Adolescents with ADHD**  
Stephen Becker, Cincinnati Children’s Hospital Medical Center

**Sleep Outcome in Clinical Trials with 12 and 16 Hour Mph-Mlr**  
Margaret Weiss, Cambridge Health Alliance

**Do Stimulants Work for ADHD in Adults with Sleep Problems?**  
Craig Surman, Massachusetts General Hospital

**What’s new in Behavioural Sleep Interventions for Children with ADHD?**  
Emma Sciberras, Deakin University

**Overall Abstract:**

This session will focus on ADHD and Sleep through the lifespan, highlighting a marked increase in research on sleep in ADHD samples and implications for treatment. Dr. Stein will provide a brief overview highlighting methodological issues in studying sleep and ADHD. Subjective and objective measures will be discussed as well as patient selection and study design (e.g., dose–response vs flexible dose, duration of trial). Then Dr. Sciberras will discuss behavioral sleep interventions for children with ADHD, which are often recommended as first line treatment. Dr. Weiss will then provide a summary of findings from studies of sleep as an adverse event versus sleep as an outcome, and address factors related to the heterogeneity of sleep effects found in ADHD studies. She will be followed by Dr. Becker, who will address the sleep problems in adolescents with ADHD, and describe his research on the important and often difficult to treat ADHD subgroup. Out last speaker with be Dr. Surman, who will describe a clinical trial with adults, and the relevance and importance of assessing sleep problems at baseline. This will be followed by a brief discussion among panel members and the audience on developmental differences in treating ADHD and algorithms for addressing sleep problems in patients with ADHD.
Learning Objectives:
- Increase familiarity with the relationships between sleep, ADHD, and its treatment.
- Increase understanding of what we have learned about sleep from clinical trials of ADHD treatment that can inform treatment decisions.
- Develop skills in assessing sleep problems throughout the lifespan and proving behavioral and pharmacological interventions.

12:30 p.m. - 2:30 p.m.  THE CHANGING LEGAL CLIMATE OF MARIJUANA USE IN ITS IMPACT FOR OUR PATIENTS WITH ADHD
Lincoln 2-4

Chair: Frances Levin, Columbia University Medical Center

Cannabis and Canada: Science, Politics, Business Helping America Avoid the Potholes!
Sam Chang, University of Calgary

Cannabis and Cannabidiol: Pharmacology and Regulatory Status
Elise Weerts, Johns Hopkins University School of Medicine

The Changing Legal Climate of Marijuana Use and Its Impact for Our Patients with ADHD
Kevin Hill, Beth Israel Deaconess Medical Center & Harvard Medical School

Mental Health Implications of Marijuana Legalization in Adolescents and Young Adults
Paula Riggs, University of Colorado School of Medicine

Overall Abstract:
As more states have legalized marijuana both for both medical and recreational use, there is an increased need for clinicians to understand the current legislative changes surrounding marijuana, the pharmacology of marijuana, and how the legislative changes and variations in marijuana’s constituents and potency may impact their patients’ psychiatric and medical conditions. Dr. Weerts will focus on the pharmacology of cannabis and its most studied key constituents, 9-tetrahydrocannabinol (THC) and cannabidiol and will provide an update on the regulatory status of cannabis and cannabidiol at the federal and state levels. Dr. Hill will describe the
medical and psychiatric conditions that cannabis is currently being use for, despite little or no support. Dr. Wang will then provide the Canadian experience with its Canadian Cannabis Policy and what the lessons might be learned for the United States. Finally, Dr. Riggs will describe the increased rates of cannabis use with the rapid expansion of marijuana legalization, particularly in adolescent and college-age youth. There is clear increased risk for psychosis with early onset and chronic use of potent products, and ongoing use negatively impacts other psychiatric disorders. How to address the treatment of individuals with ADHD and other psychiatric disorders in the context of ongoing cannabis use will be considered.

**Learning Objectives:**

- To gain knowledge of the pharmacologic properties of marijuana and its key constituents.
- To be aware of the changing legal landscape of marijuana in the United States and the impact this might have for public health.
- To be aware of potential approaches in assessing and treatment adolescents and adults with psychiatric disorders in the setting of cannabis use/cannabis use disorders.
F1. Norbinaltorphimine, a Selective Kappa-Opioid Receptor Antagonist Shows Efficacy as a long-Acting, Non-Stimulant Treatment in Preclinical Models of ADHD and Autism
Deirdre McCarthy*1, Lin Zhang1, Mia Trupiano1, Ayla Scholma1, Pradeep Bhide1, Thomas Spencer2, Joseph Biederman2
1Center for Brain Repair, Florida State University College of Medicine, 2Massachusetts General Hospital

Feng Zhang1, Norberto J. DeSousa2, F. Randy Sallee2, David Lickrish2, Bev Incledon*2
1College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, University of Texas at Austin, 2Ironshore Pharmaceuticals & Development Inc.

F3. Effect of Discontinuation Versus Maintenance of Pharmacological Treatment on Quality of Life After Symptomatic Remission in Children, Adolescent, and Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Takuya Saito*1, Noa Tsujii2, Masahide Usami3, Hidenori Kuwabara4, Junichi Fujita5, Hideki Negoro6, Michiyo Kawamura7, Junzo Iida8, Takashi Okada9
1Hokkaido University, Graduate School of Medicine, 2Kindai University Faculty of Medicine, 3Kohnodai Hospital, National Center for Global Health and Medicine, 4Senogawa Hospital, 5Yokohama City University Hospital, 6Nara University of Education, 7Medical Sciences Group, Research Support Division, Hokkaido University Library, 8Nara Medical University, 9Nagoya University Graduate School of Medicine

F4. Intolerance of Uncertainty in Adults With Attention Deficit Hyperactivity Disorder
Julia Yu*1, Martin Katzman1Kathryn Fotinos1, Sachinithya Lokuge1, Irvin Epstein1, Brigitte van Heerden1, Jerzy Hubert1, Tia Sternat1, Catherine Cameron1, Sarah Cook1, Isaac Szpindel1, Jeremy Stewart2, Emilia Sherifi2, 1S.T.A.R.T. Clinic for Mood and Anxiety Disorders, 2Queen’s University
F5. Sleep Quality Outcomes in Adults and Adolescents With ADHD Treated With PRC-063 in Two Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studies With Six-Month Open Label Extensions
Margaret Weiss*1, Graeme Donnelly2, Joseph Reiz3
1Cambridge Health Alliance, 2Purdue Pharma (Canada), 3Perdue

F6. Evaluation of the Effect of SPN-812 (Viloxazine Extended Release) on the Pharmacokinetics of Methylphenidate in Healthy Adults
Shamia Faison1, Nicholas Fry1, Toyin Adewole1, Oyinkansola Odebo1, Jiahong Xu1, Gregory Busse*1, Stefan Schwabe1, Azmi Nasser1
1Supernus Pharmaceuticals, Inc.

F7. A Pooled Analysis of 4 Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies Assessing Efficacy of SPN-812 (Viloxazine Extended Release) in Children and Adolescents With ADHD
Azmi Nasser1, Joseph Hull*1, Fatima Chowdhry1, Toyin Adewole1, Tesfaye Liranso1, Gregory Busse1, Stefan Schwabe1
1Supernus Pharmaceuticals, Inc.

F8. A Pilot Human Abuse Potential Study in Recreational Stimulant Drug Users Assessing Safety, Pharmacokinetics and Pharmacodynamics of Intranasally Administered Manipulated Adair and Dextroamphetamine Sulfate Tablets
Timothy Whitaker*1, Jessica Kardish1, Philmore Robertson1, John Oldenhof2, Isabella Szeto2
1Vallon Pharma, 2BioPharma Services

F9. Effect of PRC-063 on Executive Functioning in Adolescents With ADHD in a Randomized, Double-Blind, Placebo Controlled, Multi-Center Study With a Six-Month Open Label Extension
Declan Quinn*1, Graeme Donnelly2, Joseph Reiz2
1University of Saskatchewan, 2Perdue

F10. A Model-Based Approach for Establishing the Clinical Response of HLD200 in the Early Morning and Late Afternoon/Evening in Children With Attention-Deficit/Hyperactivity Disorder
Roberto Gomeni*1, Norberto J. DeSousa2, F. Randy Sallee2, Bev Incledon2
1PharmacoMetrica, 2Ironshore Pharmaceuticals & Development, Inc.
POSTERS

F11. Palatability Assessment of a New Amphetamine Extended-Release Tablet Formulation
Barry Herman¹, Thomas King*¹, Judith Kando¹, Antonio Pardo¹
¹Tris Pharma, Inc.

Antonio Pardo¹, Thomas King*¹, Barry Herman¹Judith Kando¹, Eman Rafia¹, Heather Jordan², Mohammed Bouhajib²,
¹Tris Pharma, Inc., ²Pharma Medica Research, Inc.

F13. Participant Engagement and Acceptability of the Lifestyle Enhancement for ADHD Program (LEAP) to Improve Child Health Risk Behaviors
Cindy Ola*¹, Nguyen Tran¹, Tyler Sasser¹, Erin Gonzalez¹, Pooja Tandon¹, Mark Stein¹, Jason Mendoza¹, Michelle Kuhn¹, Albert HSU¹
¹Seattle Children’s Hospital

F14. Real-World Treatment Patterns and Medication Coverage Among Children and Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Jaromir Mikl*¹, Jennifer Erensen¹, Diana T Amari², Xuezhe Wang², Yingjie Ding², Frank A Corvino²
¹Adlon Therapeutics, a subsidiary of Purdue Pharma, ²Genesis Research

F15. Guanfacine-Extended Release for Treatment of Adults With ADHD
Ryan Kennedy*¹, Thomas E. Brown²
¹Brown Clinic for Attention & Related Disorders, ²Yale University School of Medicine

F16. A Literature Review and Meta-Analysis on the Effects of ADHD Medications on Functional Outcomes
Ronna Fried*¹, Heidi Boland², Maura DiSalvo², Joseph Biederman², Timothy Wilens², Stephen Faraone³
¹Massachusetts General Hospital & Harvard Medical School,
²Massachusetts General Hospital, ³SUNY Upstate Medical University
POSTERS

F17. Quantifying the Protective Effects of Stimulants on Functional Outcomes in ADHD: A Focus on Number Needed to Treat (NNT) Statistic and Sex Effects
Ronna Fried*1, Maura DiSalvo2, Joseph Biederman2, Stephen Faraone3
1Massachusetts General Hospital & Harvard Medical School, 2Massachusetts General Hospital, 3SUNY Upstate Medical University

F18. Prevalence of ADHD in Adults With Treatment-Resistant Depression in TMS clinic
Jesse McClelland*1, Kimi Hashimoto1, Zhi Chen1, Rachel Inabata1
1Psychiatry Northwest and TMS Washington

F19. Re-Examination of Subsyndromal Depression Predicting Major Depressive Disorder Development in High Risk Children
Mai Uchida*1, Maura Fitzgerald, MPH1, Joseph Biederman, MD1
1Massachusetts General Hospital

F20. The Predictive Utility of Retrospective Parent-Report Ratings of Early Temperament for ADHD Diagnostic Status in Childhood
Cara Lusby*1, Jessica Solis Sloan1, Logan Smith1, Julianna Becker1, Tatyana Bidopia1, Scott Kollins1
1Duke University Medical Center

F21. What’s in a (Symptom Example)? Exploring the Impact of DSM-5’s Parenthetical Additions on Self-Reporting of Adult ADHD Symptoms
Laura Knouse*1, Russell Barkley2
1University of Richmond, 2Virginia Commonwealth University Medical Center

F22. Neuropsychological Assessment Discriminates ADHD-I from SCT by Parent Report
Beth Krone*1, Amanda Kirschenbaum1, Logan Downes1, Quinn Downes1, Kurt Schulz1, Anne-Claude Bedard2, Iliyan Ivanov3, Jeffrey Newcorn4
1Icahn School of Medicine at Mount Sinai, 2University of Toronto, 3Mt. Sinai NYC, 4Mount Sinai Medical Center
F23. ADHD and Alcohol Use in College Students: Comparison of Screening Self-Report Measures and Psychiatric Interview
Mariely Hernandez*1, Sarah O’Neill1· Sade Dixon2, Geneva Hidalgo2, Zainab Baig2, Laurie Pierre-Paul2, Ayanna Gilmore2, 1The City College of New York/CUNY Graduate Center, 2The City College of New York

F24. Positive Illusory Bias, ADHD Symptoms, and Race: An Examination Using Polynomial Regression and Response Surface Analyses
Avery Albert*1, Oneysha Brown1, Kevin Antshel1 1Syracuse University

F25. ADHD, Bullying, and Depression: A Review and Proposed Comprehensive Model
Jessica Simmons*1, Avery Albert1, Lea Taylor1, Kevin Antshel1 1Syracuse University

F26. Text Message Patient Reported Outcome Measures in Adult ADHD – A Pilot Study
Craig Surman*1 1Massachusetts General Hospital

F27. The Effect of Noise-Cancelling Headphones on Academic and Neurocognitive Outcomes in Children and Adolescents Diagnosed With ADHD
Jessica Sloan*1, Casey Keller1, Cara Lusby1, Scott Kollins1 1Duke University Medical Center

F28. Reducing Physical Management through Home Collaboration
Benjamin Aaronson*1, Tyler Sasser1, Zoey Dunne1, Will McCloud1, Shannon Ludeman1, Caitlin Courshon1, Mark Stein1 1University of Washington

F29. Predictors of Non-Suicidal Self-Injury: Guilt Related to Alcohol Use in a College Sample With Elevated ADHD and Internalizing Symptoms
Anna Garner*1, Sara Gliese1, Andrea Chronis-Tuscano1, Elizabeth Lefler2 1University of Maryland, 2University of Northern Iowa
POSTERS

F30. Early Childhood Sleep Associated With Current Sleep Among Adolescents With and Without ADHD
Jessica Lunsford-Avery*1, Scott Kollins1, Andrew Krystal2, Mary Carskadon3,
1Duke University Medical Center, 2University of California San Francisco School of Medicine, 3Warren Alpert Medical School, Brown University

F31. Decreased Risk for Substance Use Disorders in Individuals With High-Functioning Autism Spectrum Disorder
Amy Yule*1, Joseph Biederman2, Maura DiSalvo2, Timothy Wilens2, Gagan Joshi3
1Boston University/Boston Medical Center, 2Massachusetts General Hospital, 3Harvard Medical School/Massachusetts General Hospital

F32. ADHD-Related Sex Differences in the Developmental Trajectories of Delay Discounting and Inhibitory Control
Keri Rosch*1, Karen Seymour2, Yi Zhao3, Carolyn Koch4, Alyssa Tiedemann4, Stewart Mostofsky4
1Kennedy Krieger Institute/Johns Hopkins, 2Johns Hopkins University School of Medicine, 3Johns Hopkins University, 4Kennedy Krieger Institute

F33. Unlocking Adult Patient Preferences for Long-Acting ADHD Treatments: Results of a Discrete Choice Experiment
Jennifer Erensen*1, Kathleen Beusterien2, Janelle Cambron-Mellott2, Bernadette Hallissey2, Joana Matos2, Jaromír Miklá3
1Purdue Pharma L.P., 2Kantar Health, 3Purdue Pharma L.P./Adlon Therapeutics

F34. Evaluation of the Neurobiological Origin of Comorbid Anxiety in ADHD Using the Error Related Negativity
Sophie Ziliak*1, Jasper Palmer1, Anne Arnett1
1University of Washington

F35. Parsing Heterogeneity in ADHD Using ERP Profiles
Anne Arnett*1
1University of Washington
F36. Resting-State fMRI Correlates of Clinical Response to Stimulant Treatments in Children and Adolescents With ADHD

Victor Pereira-Sanchez*, Alexandre R. Franco, Pilar de Castro Manglano, Maria Vallejo-Valdivielso, Azucena Díez-Suárez, César Soutullo, Miguel Fernandez-Martinez, María A. Fernandez-Seara, Michael Milham, F. Xavier Castellanos

1NYU Langone Child Study Center, 2Child Mind Institute, 3University of Navarra Clinic, 4New York University Child Study Center

F37. Longitudinal Growth of the Cerebellum in Children With ADHD

Rebecca Rochowiak*, Deana Crocetti, Romila Santra, Mark Mahone, Yi Zhao, Stewart Mostofsky

1Kennedy Krieger Institute, 2Johns Hopkins University, 3Center for Neurodevelopmental and Imaging Research
POSTERS

Saturday, January 18, 2019
12:30 PM – 2:30 PM
Poster Session II with Lunch

S1. In Vitro Dissolution and in Vivo Absorption of Methylphenidate from a Delayed-Release and Extended-Release Drug Delivery Platform
Jogarao Gobburu¹, Roberto Gomeni², Norberto J. DeSousa³, F. Randy Sallee², Bev Incledon³
¹Center for Translational Medicine, School of Pharmacy, University of Maryland Baltimore, ²PharmacoMetrica, ³Ironshore Pharmaceuticals & Development Inc.

S2. An In Vitro/In Vivo Correlation (IVIVC) Model for HLD200, an Evening-Dosed Delayed-Release and Extended-Release Methylphenidate
Roberto Gomeni*¹, Norberto J. DeSousa², F. Randy Sallee², Bev Incledon²
¹PharmacoMetrica, ²Ironshore Pharmaceuticals & Development, Inc.

S3. Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Adult Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo for the Treatment of ADHD
Ann Childress*¹, Graeme Donnelly², Sailaja Bhaskar²
¹Center for Psychiatry and Behavioral Medicine, Inc., ²Purdue Pharma (Canada)

S4. An Assessment of QTc Effects With SPN-812 (Viloxazine Extended Release) in Healthy Adults
Azmi Nasser¹, Shamia Faison¹, Tesfaye Liranso¹, Toyin Adewole*¹, Gregory Busse¹, Maurizio Fava², Robert Kleiman³, Stefan Schwabe¹
¹Supernus Pharmaceuticals, Inc., ²Massachusetts General Hospital, ³eResearch Technology, Inc.

S5. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P301) Assessing Efficacy and Safety of SPN-812 (Viloxazine Extended Release) in Children With ADHD
Azmi Nasser¹, Joseph Hull¹, Fatima Chowdhry*¹, Toyin Adewole¹, Tesfaye Liranso¹, Gregory Busse¹, Stefan Schwabe¹
¹Supernus Pharmaceuticals, Inc.

* Data Blitz

Page 54
S6. Functional Outcomes in Adults With ADHD Treated With PRC-063 in a Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study With a Six-Month Open-Label Extension
Margaret Weiss¹, Graeme Donnelly*²
¹Cambridge Health Alliance, ²Purdue Pharma (Canada)

Carolyn Sikes¹, Thomas Laage², Andrew Volosov², Alison Hart², Andrea Marraffino³
¹Neos Therapeutics, ²Premier Research, Research Triangle Park ³Meridien Research, Maitland

S8. Single-Dose Pharmacokinetics of Amphetamine Extended-Release Oral Suspension (AMPH EROS) in 6-12 Year Old Children With ADHD
Antonio Pardo¹, Barry Herman¹, Thomas King*¹, Eman Rafla¹, Judith Kando¹, Ann Childress²
¹Tris Pharma, Inc., ²Center for Psychiatry and Behavioral Medicine, Inc.

Barry Herman¹, Judith Kando¹, Thomas King*¹, Antonio Pardo¹
¹Tris Pharma, Inc.

Shana Carrington-Forde*¹, Elia F. Soto¹, Caroline E. Miller¹, Kijana P. Richmond¹, Michael J. Kofler¹
¹Florida State University

S11. Primary Care Prevention of Stimulant Diversion by Adolescents With ADHD: A Cluster Randomized Controlled Trial in Pediatric Practices
Brooke Molina*¹, Heidi Kipp², Sarah Pedersen¹, Heather Joseph¹, David Kolko¹, Rachel Lindstrom², Daniel Bauer³, David Liu⁴, Geetha Subramaniam⁴
POSTERS

S12. Examination of Effects of Age and Sex on Mirror Overflow During Sequential Finger Tapping in Children With and Without ADHD
Christine Chen*, Deana Crocetti¹, E. Mark Mahone¹, Stewart Mostofsky¹, Karen Seymour², Yi Zhao³,候 Kennedy Krieger Institute, ²Johns Hopkins University School of Medicine, ³Johns Hopkins University

S13. Basic Processes as Foundations of Cognitive Impairment in Adult ADHD
Marah Butzbach*, Anselm Fuermaier¹, Lara Tucha¹, Oliver Tucha¹, Steffen Aschenbrenner², Matthias Weisbrod³,候 University of Groningen, ²SRH Clinic Karlsbad-Langensteinbach, Germany, ³University of Heidelberg, Germany

S14. The Association Between ADHD Medication and Psychosis
Kelsey Wiggs*, Brian D’Onofrio¹, Patrick Quinn¹, Kwan Hur², Robert Gibbons², Zheng Chang³, Patrick Larsson⁴,候 Indiana University, ²University of Chicago, ³Karolinska Institute, ⁴Örebro University

* S15. Clinical Characteristics Associated With Receipt of Behavioral Healthcare Embedded in Pediatric Primary Care Versus Outside of the Practice for Teens Stimulant-Treated for ADHD
Heather Joseph*, Brooke Molina¹, Sarah Pedersen¹, David Kolko¹, Rachel Lindstrom², Heidi Kipp², David Liu³, Sutha Subramaniam⁴,候 University of Pittsburgh, ²University of Pittsburgh Medical Center, Western Psychiatric Institute & Clinic, ³National Institute on Drug Abuse

S16. Bidirectional Associations Between Maternal Mental Health and Child Sleep Problems in Children With ADHD: A Longitudinal Study
Christina Martin*, Nicole Papadopoulos¹, Melissa Mulraney², Nicole Rinehart¹, Emma Sciberras¹,候 Deakin University, Australia, ²Murdoch Children’s Research Institute, Australia

* Data Blitz

Page 56
POSTERS

S17. Can the Cantab Identify Adults With Attention-Deficit/Hyperactivity Disorder? A Controlled Study
Ronna Fried*, Maura DiSalvo, Joseph Biederman
1Massachusetts General Hospital & Harvard Medical School,
2Massachusetts General Hospital

S18. Towards Operationalizing Deficient Emotional Self-Regulation in Newly Referred Adults With ADHD: An ROC Curve Analysis
Joseph Biederman, Mai Uchida, Maura DiSalvo, Craig Surman, Ronna Fried*
1Massachusetts General Hospital, 2Massachusetts General Hospital & Harvard Medical School, 3SUNY Upstate Medical University

S19. Predicting ADHD-Related Symptoms From Free-Text Responses to Internally and Externally Focused Questions
Matthew Engelhard*, Scott Kollins
1Duke University

S20. Patterns of Health Services Use Before age 1 in Children Later Diagnosed With ADHD
Matthew Engelhard*, Samuel Berchuck, Jyotsna Garg, Ricardo Henao, Shelley Rusincovitch, Geraldine Dawson, Scott Kollins
1Duke University

* S21. Temperament Traits as Markers of Liability for Psychiatric Comorbidity in Children With ADHD
Tara Rutter*, Anne Arnett
1University of Washington

S22. Exploring Gender-Related Differences in the Behavioural Manifestation of ADHD
Margaret D. Weiss, Robert Ramkhalawansingh*, Joanna Solomon
1University of British Columbia, 2MHS

S23. Examining the Associations Among Social Skills, ADHD Symptoms, and Academic Performance in Children
Kijana Richmond*, Elia Soto, Elizabeth Chan, Carolyn Marsh, Caroline Miller, Michael J. Kofler
1Florida State University, Psychology & Neuroscience, 2Florida State University

* Data Blitz
Page 57
S24. Parental Preferences and Utilization of Treatments for Children With ADHD
Stewart Pisecco*1
1Stewart Pisecco, Ph.D.

S25. The Different Responsiveness of Reward and Punishment to Procrastination in Adolescents and Adult High and Low ADHD Tendencies
Mana Oguchi*1, Toru Takahashi2, Yusuke Nitta2, Hiroaki Kumano2
1Waseda University, 2Waseda University, Japan Society for The Promotion of Science, 3Faculty of Human Sciences, Waseda University

S26. Race/Ethnicity Differences in ADHD Severity and Impairment Among College Students
Laurie Pierre-Paul*1, Sade Dixon1, Geneva Hidalgo1, Zainab Baig1, Ayanna Gilmore1, Mariely Hernandez2, O'Neill2
1The City College of New York, 2The City College of New York/CUNY Graduate Center

S27. Are ADHD Severity and BMI Associated With Binge Eating Behavior Among College Students?
Carolina Rozario*1, Elaine Johnson1, Breanna Badripersaud1, Nadine Alkouchiri1, Geneva Hidalgo1, Sarah O'Neill2
1The City College of New York, 2The City College of New York/CUNY Graduate Center

S28. Working Memory/Loss of Cognitive set, but not Global Sluggish Cognitive Tempo, is Associated With Reward Dependence in Children With ADHD, Predominantly Inattentive Presentation
Keith McBurnett*1, Melissa Dvorsky1, Madeline Spiess1, Linda Pfiffner1
1University of California, San Francisco

S29. Increased Cognitive Enhancing and Reinforcing Effects of Initial Nicotine Exposure Among Young Adults With ADHD Compared to Matched Peers: Laboratory Evidence for a Pathway of Risk for Smoking
Maggie Sweitzer*1, F. Joseph McClernon1Scott Kollins1, Kenneth Perkins2, 1Duke University Medical Center, 2University of Pittsburgh Medical Center

* Data Blitz
POSTERS

★ S30. Untreatable ADHD Becomes Treatable When Alpha-Agonists are Used Concurrent With Stimulants
Jesse McClelland*1, Rachel Inabata1, Kimi Hashimoto1
1Psychiatry Northwest and TMS Washington

S31. Increased Behavioral Sensitivity to Repeated Experiences of Punishment in Children With ADHD: Experimental Studies Using the Matching Law
Emi Furukawa*1, Gail Tripp1, Shizuka Shimabukuro1, Brent Alsop2Paula Sowerby3, Cara Moffat4
1Okinawa Institute of Science and Technology Graduate University, 2University of Otago, 3Child and Adolescent Mental Health Services, Blenheim, 4Psychology Associates, Dunedin

S32. Memory Retrieval Deficits in Children With ADHD: The Mediating Role of Working Memory
Nicole Hale*1, Dr. Mark Rapport1
1University of Central Florida

S33. Neurobiological Basis of Reinforcement-Based Decision Making in Adults With ADHD Treated With Lisdexamfetamine Dimesylate
Iliyan Ivanov*1, Jeffery Newcorn* first co-author2, Beth Krone2, Juan Pedraza2, Kurt Schulz2, Xiaobo Liu3, Stephanie Duhoux4, Steward White5Anne-Claude Bedard4Lenard Adler7, James Blair8
1Mt. Sinai NYC, 2Icahn School of Medicine at Mount Sinai, 3New Jersey Institute of Technology, NJ, 4Tris Pharma, 5Developmental Clinical Neuroscience Laboratory, Boys Town National Research Hospital University of Toronto, 7NYU School of Medicine, 8Center for Neurobehavioral Research, Boys Town National Research Hospital

S34. Sex Differences in Impulsive Response to Reward in Children With ADHD and Associations With Fronto-Striatal Structural Connectivity
Joshua Robinson*1, Deana Crocetti1, Vikas Vattipally1Stewart Mostofsky1, Karen Seymour2, Keri Rosch3
1Kennedy Krieger Institute, 2Johns Hopkins University School of Medicine, 3Kennedy Krieger Institute/Johns Hopkins

★ Data Blitz
Page 59
POSTERS

S35. Differential Developmental Trajectories of Irritability, Depression and Anxiety in Boys Versus Girls With ADHD
Karen Seymour*, Keri Rosch, Stewart Mostofsky, Yi Zhao, Alyssa Tiedemann, Jonathan Phillips, Alyssa DeRonda
1Johns Hopkins University School of Medicine, 2Kennedy Krieger Institute/Johns Hopkins, 3Indiana University School of Medicine, 4Kennedy Krieger Institute

S36. The Characteristics and Unique Impairments of Comorbid Adult ADHD and Sluggish Cognitive Tempo: An Interim Analysis
Lenard Adler*, Terry L. Leon, Michael Silverstein, Beth Krone, Jeffery Newcorn
1NYU School of Medicine, 2Drexel University 3Icahn School of Medicine at Mount Sinai

S37. Developmental Trajectory of Subtle Motor Signs in Attention-Deficit Hyperactivity Disorder: A Longitudinal Study from Childhood to Adolescence
Jewel Crasta*, Stacy Suskauer, Keri Rosch, Stewart Mostofsky, Yi Zhao
1Kennedy Krieger Institute/Johns Hopkins, 2Johns Hopkins University
AUTHOR INDEX

TO BE DONE
AUTHOR INDEX
Save the Date!

APSARD 2021: January 15-17, 2021
APSARD 2022: January 14-16, 2022
The Marriott Washington Wardman Park
Washington, D.C., USA

APSARD
The American Professional Society of ADHD and Related Disorders

BECOME A MEMBER OF APSARD TODAY!

APSARD is Working to Improve the Quality of Care for ADHD Patients through:
Shared Research.
Best Practices.
Evidence-Based Education and Training.

Member benefits include:
• Online Subscription to the Journal of Attention Disorders (JAD)
• Discounted registration for the APSARD Annual Meeting
• Free Conference Materials
• Access to the members only website
• Participation in Blogs and Forums

For membership information:
Call 615-324-2365 or email info@apsard.org

www.apsard.org